NASHVILLE, Tenn.--(BUSINESS WIRE)--The Sarah Cannon Research Institute will enroll 1,800 breast cancer patients for its TITAN study, a clinical research trial investigating the role of ixabepilone (Ixempra) in the treatment of early breast cancer.
NASHVILLE, Tenn.--(BUSINESS WIRE)--The Sarah Cannon Research Institute will enroll 1,800 breast cancer patients for its TITAN study, a clinical research trial investigating the role of ixabepilone (Ixempra) in the treatment of early breast cancer.
